NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Brasure M, Shamliyan TA, Butler ME, et al. Preventive Pharmacological Treatments for Migraine in Adults: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 103 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr. (Future Research Needs Papers, No. 35.)

Cover of Preventive Pharmacological Treatments for Migraine in Adults: Future Research Needs

Preventive Pharmacological Treatments for Migraine in Adults: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 103 [Internet].

Show details

References

1.
Shamliyan TA, Kane RL, Taylor FR. Migraine in Adults: Preventive Pharmacologic Treatments. Comparative Effectiveness Review No. 103. Rockville, MD: Agency for Healthcare Research and Quality; 2013. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2007-10064-I.) AHRQ Publication No. 13-EHC068-EF.
2.
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia. (2nd edition) 2004;24 Suppl 1:9–160. [PubMed: 14979299]
3.
Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009 May;27(2):429–43. [PubMed: 19289224]
4.
Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology. 2000;55(9 Suppl 2):S29–35. [PubMed: 11089517]
5.
Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007 Mar;47(3):355–63. [PubMed: 17371352]
6.
Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002 Mar 26;58(6):885–94. [PubMed: 11914403]
7.
Bigal ME, Lipton RB, Winner P, et al. Migraine in adolescents: association with socioeconomic status and family history. Neurology. 2007 Jul 3;69(1):16–25. [PubMed: 17606878]
8.
Hernandez-Latorre MA, Roig M. Natural history of migraine in childhood. Cephalalgia. 2000 Jul;20(6):573–9. [PubMed: 11075841]
9.
Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 Jun;26(6):742–6. [PubMed: 16686915]
10.
Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008 Aug 19;71(8):559–66. [PubMed: 18711108]
11.
Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010 May;30(5):599–609. [PubMed: 19614702]
12.
Stewart WF, Ricci JA, Chee E, et al. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med. 2003 Dec;45(12):1234–46. [PubMed: 14665809]
13.
Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999 Apr 26;159(8):813–8. [PubMed: 10219926]
14.
Burton WN, Landy SH, Downs KE, et al. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009 May;84(5):436–45. [PMC free article: PMC2676126] [PubMed: 19411440]
15.
Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343–9. [PubMed: 17261680]
16.
Goadsby PJ, Raskin NH. Chapter 15 Headache. In: Fauci AS, Braunwald E, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 17th ed. New York: The McGraw-Hill Companies; 2008.
17.
Solomon S. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2007 May;27(5):469. (Comment on: Cephalagia 2006 Jun:26(6):742–6) author reply -70. [PubMed: 17448186]
18.
U.S. Food and Drug Administration. FDA News Release: FDA Approves Botox to Treat Chronic Migraine. [Accessed on February 1, 2011]. www​.fda.gov/NewsEvents​/Newsroom/PressAnnouncements​/ucm229782.htm.
19.
Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003 Feb 11;60(3):441–8. [PubMed: 12578925]
20.
Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol. 1994;34 Suppl 2:6–11. [PubMed: 7835383]
21.
Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmacological treatment options. BMC Medicine. 2009;7:71. [PMC free article: PMC2784479] [PubMed: 19917094]
22.
Sanchez-Del-Rio M, Reuter U, Moskowitz MA. New insights into migraine pathophysiology. Curr Opin Neurol. 2006 Jun;19(3):294–8. [PubMed: 16702838]
23.
Rapoport AM. Acute and prophylactic treatments for migraine: present and future. Neurol Sci. 2008 May;29 Suppl 1:S110–22. [PubMed: 18545911]
24.
DeMaagd G. The pharmacological management of migraine, part 2: preventative therapy. Pharmacy and Therapeutics. 2008;33(8):480. [PMC free article: PMC2730105] [PubMed: 19750179]
25.
Stafford RS. Regulating off-label drug use--rethinking the role of the FDA. N Engl J Med. 2008 Apr 3;358(14):1427–9. [PubMed: 18385495]
26.
Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008 May;28(5):484–95. [PubMed: 18294250]
27.
Schroeder BM. AAFP/ACP-ASIM release guidelines on the management and prevention of migraines. Am Fam Physician. 2003 Mar 15;67(6):1392, 5–7. [PubMed: 12674472]
28.
Morey SS. Guidelines on migraine: part 4. General principles of preventive therapy. Am Fam Physician. 2000 Nov 15;62(10):2359–60. [PubMed: 11126860]
29.
Hazard E, Munakata J, Bigal ME, et al. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health. 2009 Jan;12(1):55–64. [PubMed: 18671771]
30.
Lainez MJ, Freitag FG, Pfeil J, et al. Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol. 2007 Aug;14(8):900–6. [PubMed: 17662012]
31.
Luykx J, Mason M, Ferrari MD, et al. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther. 2009 Mar;85(3):283–8. [PubMed: 18987621]
32.
Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology. Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004 Dec 28;63(12):2215–24. [PubMed: 15623677]
33.
Gunner KB, Smith HD, Ferguson LE. Practice guideline for diagnosis and management of migraine headaches in children and adolescents: Part two. J Pediatr Health Care. 2008 Jan–Feb;22(1):52–9. [PubMed: 18174091]
34.
Geraud G, Lanteri-Minet M, Lucas C, et al. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 2004 Aug;26(8):1305–18. [PubMed: 15476911]
35.
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009 Sep;16(9):968–81. [PubMed: 19708964]
36.
Dowson AJ, Lipscombe S, Sender J, et al. New guidelines for the management of migraine in primary care. Curr Med Res Opin. 2002;18(7):414–39. [PubMed: 12487508]
37.
Pascual J, El Berdei Y, Gomez-Sanchez JC. How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate. J Headache Pain. 2007 Apr;8(2):90–3. [PMC free article: PMC3476126] [PubMed: 17221343]
38.
O’Haire C, McPheeters M, Nakamoto EK, et al. Methods for Engaging Stakeholders To Identify and Prioritize Future Research Needs. Methods Future Research Needs Report No. 4. Rockville, MD: Agency for Healthcare Research and Quality; Jun, 2011. (Prepared by the Oregon Evidence-based Practice Center and the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10057-I.) AHRQ Publication No. 11-EHC044-EF. www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
39.
NINDS Headache Common Data Element (CDE) Project. Recommendations from the Headache Preventive Therapies Subgroup:Overview of the Headache Preventive Therapies Recommendations. NINDS. 2012. www​.commondataelementsninds​.nih.gov/Headache​.aspx#tab=Data_Standards.
40.
Andrews J. Prioritization Criteria Methodology for Future Research Needs Proposals Within the Effective Health Care Program. Methods Future Research Needs Report No. 10. Rockville, MD: Agency for Healthcare Research and Quality; Jan, 2013. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I.) AHRQ Publication No. 12(13)-EHC152-EF. http:​//effectivehealthcare​.ahrq.gov/search-for-guides-reviews-and-reports​/?pageaction​=displayproduct&productid​=1374. [PubMed: 23367528]
41.
Cecil G.Sheps Center for Health Services Research; The University of North Carolina at Chapel Hill. Prioritization Software. 2009.
42.
Carey T, Sanders GD, Viswanathan M, et al. Framework for Considering Study Designs for Future Research Needs Methods. Future Research Needs Paper No. 8. Rockville, MD: Agency for Healthcare Research and Quality; Mar, 2012. (Prepared by the RTI–UNC Evidence-based Practice Center under Contract No. 290-2007-10056-I.) AHRQ Publication No. 12-EHC048-EF. www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
43.
Manack A, Turkel C, Silberstein S. The evolution of chronic migraine: classification and nomenclature. Headache. 2009 Sep;49(8):1206–13. [PubMed: 19438732]
44.
Manzoni GC, Grisendi I, Torelli P. ICHD-3: what changes do we need regarding migraine? Current Pain & Headache Reports. 2011 Jun;15(3):170–6. [PubMed: 21365366]
45.
American Association for the Study of Headache. Headache. 2006;46(7)
46.
Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache. 2011 Jul–Aug;51 Suppl 2:77–83. [PubMed: 21770929]
47.
Pringsheim T, Davenport WJ, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. Canadian Journal of Neurological Sciences. 2012 Mar;39(2 Suppl 2):S1–59. [PubMed: 22683887]
48.
Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012 Jan;32(1):6–38. [PubMed: 22384463]
49.
Patient-Centered Outcomes Research Institute. Public comment draft report of the Patient-Centered Outcomes Research Institute (PCORI) Methodology Committee presented on July 23, 2012, and revised thereafter. www​.pcori.org/assets​/MethodologyReport-Comment.pdf.
50.
Office of Management and Budget. Standards and guidelines for statistical surveys. 2006. [Accessed on May 16 2012]. www​.whitehouse.gov/sites​/default/files/omb​/inforeg/statpolicy​/standards_stat_surveys.pdf.
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (766K)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...